Search Results for “H19-423_V1.0 Latest Test Testking 🍀 H19-423_V1.0 Practical Information 📄 H19-423_V1.0 Test Price 🕔 Go to website ☀ www.pdfvce.com ️☀️ open and search for ➠ H19-423_V1.0 🠰 to download for free 🎤H19-423_V1.0 Download Pdf” – Page 22

Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA²LEN taskforce position paper

Braido, F.+, Bousquet, P. J., Brzoza, Z., Canonica, G. W., Compalati, E., Fiocchi, A., Fokkens, W., Gerth van Wijk, R., La Grutta, S., Lombardi, C., Maurer, M. Pinto, A. M., Ridolo, E., Senna, G. E., Terreehorst, I., Todo Bom, A., Bousquet, J., Zuberbier, T., and Baiardini, I.: Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA²LEN taskforce position paper. Allergy 2010: 65; 959-968. IF: 6.29

o.099

27.	Młynek, A., Maurer, M., and Zalewska, A.: Update on chronic urticaria: focusing on mechanisms. Curr. Opin. Allergy Clin. Immunol. 2008: 8; 433-437. IF: 3.50

31.	Hakim-Rad, K., Metz, M., and Maurer, M.: Mast Cells: Makers and Breakers of allergic inflammation. Curr. Opin. Allergy Clin. Immunol. 2009: 9; 427-430. IF: 3.15

111.	Maurer, M., Church, M. K., Marsland, A. M., Sussman, G., Siebenhaar, F., Vestergaard, C., and Broom, B.: Questions and answers in chronic urticaria: where do we stand and where do we go? J. Eur. Acad. Dermatol. Venereol. 2016: 30, Suppl. 5; 7-15. IF: 3.52

r.111

105.	Maurer, M., Vena, G. A., Cassano, N., and Zuberbier, T.: Current and future therapies for treating chronic spontaneous urticaria. Expert Opin. Pharmacother. 2016: 17; 1131-1139. IF: 3.89

r.105

99.	Weller, K., Zuberbier, T., and Maurer, M.: Clinically relevant outcome measures for assessing disease activity, disease control and quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedema. Curr. Opin. Allergy Clin. Immunol. 2015: 15; 220-226. IF: 2.77

r.099

85.	Maurer, M.: Urticaria and angioedema. History of allergy. Chem. Immunol. Allergy 2014: 100, 101-104. IF N/A

EAACI biological guidelines – dupilumab for children and adults with moderate-to-severe atopic dermatitis

422.

Agache, I.⁺, Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger T., Eyerich, K. Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Warner, A., Werfel, T., Palomares, O., and Jutel, M.: EAACI biological guidelines – dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy 2021: 76; 988-1009. IF: 14.71

o.422

249	Kessel, A.+, Graif, Y., Vadasz, Z., Schichter-Konfino, V., Almog, M., Cohen, S., Teplitski, V., Stein, N., Baiardini, I. Maurer, M. and Toubi, E.: Adaption and validation of the Israeli version of the chronic urticaria quality of life questionnaire (CU-Q2oL). IMAJ 2016: 18; 461-465. IF: 1.03

76.	Maurer, M., Magerl, M., Metz, M., Weller, K., and Siebenhaar, F.: Miltefosine: A novel treatment option for mast cell-mediated diseases. J. Dermatol. Treat. 2013: 24; 244-249. IF: 1.76

Results

Search Results for: H19-423_V1.0 Latest Test Testking 🍀 H19-423_V1.0 Practical Information 📄 H19-423_V1.0 Test Price 🕔 Go to website ☀ www.pdfvce.com ️☀️ open and search for ➠ H19-423_V1.0 🠰 to download for free 🎤H19-423_V1.0 Download Pdf – Page 22

Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA²LEN taskforce position paper

Update on chronic urticaria: focusing on mechanisms

Mast cells: makers and breakers of allergic inflammation

Questions and answers in chronic urticaria: where do we stand and where do we go?

Current and future therapies for treating chronic spontaneous urticaria

Clinically relevant outcome measures for assessing disease activity, disease control and quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedema

Urticaria and angioedema

EAACI biological guidelines – dupilumab for children and adults with moderate-to-severe atopic dermatitis

Adaption and validation of the Israeli version of the chronic urticaria quality of life questionnaire (CU-Q2oL)

A novel treatment option for mast cell-mediated diseases